JP2024544698A5 - - Google Patents
Info
- Publication number
- JP2024544698A5 JP2024544698A5 JP2024534196A JP2024534196A JP2024544698A5 JP 2024544698 A5 JP2024544698 A5 JP 2024544698A5 JP 2024534196 A JP2024534196 A JP 2024534196A JP 2024534196 A JP2024534196 A JP 2024534196A JP 2024544698 A5 JP2024544698 A5 JP 2024544698A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2117828.0 | 2021-12-09 | ||
| GB2117828.0A GB2613616A (en) | 2021-12-09 | 2021-12-09 | New formulations |
| PCT/EP2022/085133 WO2023105035A1 (en) | 2021-12-09 | 2022-12-09 | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024544698A JP2024544698A (ja) | 2024-12-03 |
| JP2024544698A5 true JP2024544698A5 (https=) | 2025-12-05 |
| JPWO2023105035A5 JPWO2023105035A5 (https=) | 2025-12-05 |
Family
ID=80079964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534196A Pending JP2024544698A (ja) | 2021-12-09 | 2022-12-09 | 高血糖症及び２型糖尿病の治療のための（ｒ）－２－（ｔｅｒｔ－ブチルアミノ）－１－（５－フルオロピリジン－３－イル）－エタン－１－オールヘミ酒石酸塩の結晶形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250042856A1 (https=) |
| EP (1) | EP4444699A1 (https=) |
| JP (1) | JP2024544698A (https=) |
| KR (1) | KR20240116482A (https=) |
| CN (1) | CN118525004A (https=) |
| AU (1) | AU2022405700A1 (https=) |
| CA (1) | CA3241501A1 (https=) |
| GB (1) | GB2613616A (https=) |
| IL (1) | IL313292A (https=) |
| MX (1) | MX2024006960A (https=) |
| WO (1) | WO2023105035A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202303229D0 (en) * | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| WO2020198466A1 (en) * | 2019-03-27 | 2020-10-01 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
-
2021
- 2021-12-09 GB GB2117828.0A patent/GB2613616A/en active Pending
-
2022
- 2022-12-09 AU AU2022405700A patent/AU2022405700A1/en active Pending
- 2022-12-09 CA CA3241501A patent/CA3241501A1/en active Pending
- 2022-12-09 MX MX2024006960A patent/MX2024006960A/es unknown
- 2022-12-09 CN CN202280081693.4A patent/CN118525004A/zh active Pending
- 2022-12-09 WO PCT/EP2022/085133 patent/WO2023105035A1/en not_active Ceased
- 2022-12-09 EP EP22835607.7A patent/EP4444699A1/en active Pending
- 2022-12-09 IL IL313292A patent/IL313292A/en unknown
- 2022-12-09 US US18/717,134 patent/US20250042856A1/en active Pending
- 2022-12-09 JP JP2024534196A patent/JP2024544698A/ja active Pending
- 2022-12-09 KR KR1020247020161A patent/KR20240116482A/ko active Pending